TG Therapeutics | TGTX - Sales Revenues


TG Therapeutics reported $194.8M in Sales Revenues for its fiscal quarter ending in March of 2026.





Sales Change Date
AbbVie USD 15B 1.62B Mar/2026
Alaunos Therapeutics USD 2K 2K Mar/2025
Amgen USD 8.62B 1.28B Mar/2026
Ardelyx USD 94.47M 30.74M Mar/2026
Arrowhead Research USD 73.74M 190.29M Mar/2026
Bayer EUR 13.41B 1.97B Mar/2026
Biogen USD 2.25B 30M Mar/2026
Corcept Therapeutics USD 164.9M 37.22M Mar/2026
Curis USD 1.14M 1.41M Dec/2025
Gilead Sciences USD 7B 930M Mar/2026
J&J USD 24.1B 500M Mar/2026
Karyopharm Therapeutics USD 34.08M 3.54M Dec/2025
Novartis USD 13.11B 226M Mar/2026
Novavax USD 147.14M 76.69M Dec/2025
PTC Therapeutics USD 273M 108.3M Mar/2026
Puma Biotechnology USD 80.54M 33.46M Sep/2024
Regeneron Pharmaceuticals USD 3.6B 280M Mar/2026
Roche Holding CHF 15.65B 274.5M Dec/2025
TG Therapeutics USD 194.8M 2.23M Mar/2026
Verastem USD 17.54M 7.53M Dec/2025
Vertex Pharmaceuticals USD 2.99B 200M Mar/2026